https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-03-24 / Clin. Cancer Res. 2009 Apr;15(7):2531-40
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-03-24 / Clin. Cancer Res. 2009 Apr;15(7):2531-402009-03-24 00:00:002019-02-15 08:49:29Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-03-16 / Oncologist 2009 Mar;14(3):240-52
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-03-16 / Oncologist 2009 Mar;14(3):240-522009-03-16 00:00:002019-02-15 08:32:27Immunotherapy of acute myeloid leukemia: current approaches
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-03-11 / Blood 2009 May;113(21):5167-75
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-03-11 / Blood 2009 May;113(21):5167-752009-03-11 00:00:002019-02-15 08:44:19Costimulatory ligand CD70 allows induction of CD8+ T-cell immunity by immature dendritic cells in a vaccination setting
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-03-11 / Cancer Chemother. Pharmacol. 2009 Nov;64(6):1079-83
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-03-11 / Cancer Chemother. Pharmacol. 2009 Nov;64(6):1079-832009-03-11 00:00:002019-02-15 09:17:32Preliminary results of M-VAC chemotherapy combined with mild hyperthermia, a new therapeutic strategy for advanced or metastatic transitional cell carcinoma of the urothelium
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-03-03 / Cancer Res. 2009 Mar;69(6):2685-93
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-03-03 / Cancer Res. 2009 Mar;69(6):2685-932009-03-03 00:00:002019-02-15 08:38:01Coordination of intratumoral immune reaction and human colorectal cancer recurrence
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-03-01 / Future Oncol 2009 Mar;5(2):187-96
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-03-01 / Future Oncol 2009 Mar;5(2):187-962009-03-01 00:00:002019-02-15 09:23:58Promising novel immunotherapies and combinations for prostate cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-03-01 / Expert Opin Biol Ther 2009 Mar;9(3):331-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-03-01 / Expert Opin Biol Ther 2009 Mar;9(3):331-92009-03-01 00:00:002019-02-15 09:23:39Countering tumor-induced immunosuppression during immunotherapy for pancreatic cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-02-26 / Gene Ther. 2009 Jun;16(6):796-804
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-02-26 / Gene Ther. 2009 Jun;16(6):796-8042009-02-26 00:00:002009-02-26 00:00:00Genetically engineered Newcastle disease virus for malignant melanoma therapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-02-25 / Strahlenther Onkol 2009 Feb;185(2):120-6
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-02-25 / Strahlenther Onkol 2009 Feb;185(2):120-62009-02-25 00:00:002019-02-15 09:17:37Strong synergy of heat and modulated electromagnetic field in tumor cell killing
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-02-19 / Cancer Immunol. Immunother. 2009 Oct;58(10):1669-77
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-02-19 / Cancer Immunol. Immunother. 2009 Oct;58(10):1669-772009-02-19 00:00:002019-02-15 08:32:26Dramatic efficacy improvement of a DC-based vaccine against AML by CD25 T cell depletion allowing the induction of a long-lasting T cell response
